Sign In
24 Dec 2015 07:00
Ergomed Awards Share Options
Guildford, UK - 24 December 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that the following awards have been made under its unapproved executive share option scheme to certain directors of the Company.
The awards consist of share options over the Company's ordinary shares of 1p each (the "Options"), with an exercise price of 169 pence (being the closing price on 23 December 2015) which will vest on 3 June 2018 but are not subject to any performance criteria. Once vested, the Options will be exercisable until 23 December 2025.
Director | Award of Options | Resulting interest in options | Current shareholding in the Company |
Neil Clark - Chief Financial Officer | 150,000 | 1,150,000 | 91,912 |
Andrew Mackie - Chief Business Officer | 125,000 | 125,000 | NIL |
In total 275,000 Options were granted yesterday, representing 0.96% of the issued share capital.
For further information, please contact:
Hume Brophy - for UK enquiries
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
ergomed@humebrophy.com
Stifel
NOMAD/Broker to the Company
Jonathan Senior, Stewart Wallace and Ben Maddison
Tel: +44 207 710 7600
MC Services - for Continental European enquiries
Anne Hennecke
Tel: +49 211 529252 22
anne.hennecke@mc-services.eu
Follow the stocks
